105 related articles for article (PubMed ID: 25406660)
1. Real-time cytotoxicity assays in human whole blood.
Hsiao CW; Lo YT; Liu H; Hsiao SC
J Vis Exp; 2014 Nov; (93):e51941. PubMed ID: 25406660
[TBL] [Abstract][Full Text] [Related]
2. Real time assays for quantifying cytotoxicity with single cell resolution.
Hsiao SC; Liu H; Holstlaw TA; Liu C; Francis CY; Francis MB
PLoS One; 2013; 8(6):e66739. PubMed ID: 23826123
[TBL] [Abstract][Full Text] [Related]
3. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays.
Dengler WA; Schulte J; Berger DP; Mertelsmann R; Fiebig HH
Anticancer Drugs; 1995 Aug; 6(4):522-32. PubMed ID: 7579556
[TBL] [Abstract][Full Text] [Related]
4. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
5. A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells.
Zimmermann SY; Esser R; Rohrbach E; Klingebiel T; Koehl U
J Immunol Methods; 2005 Jan; 296(1-2):63-76. PubMed ID: 15680151
[TBL] [Abstract][Full Text] [Related]
6. A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening.
Li Y; Liu PC; Shen Y; Snavely MD; Hiraga K
J Biomol Screen; 2015 Aug; 20(7):869-75. PubMed ID: 26024945
[TBL] [Abstract][Full Text] [Related]
7. Chip-based dynamic real-time quantification of drug-induced cytotoxicity in human tumor cells.
Wlodkowic D; Skommer J; McGuinness D; Faley S; Kolch W; Darzynkiewicz Z; Cooper JM
Anal Chem; 2009 Aug; 81(16):6952-9. PubMed ID: 19572560
[TBL] [Abstract][Full Text] [Related]
8. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
9. Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens.
Tomska K; Scheinost S; Zenz T
Methods Mol Biol; 2019; 1956():351-362. PubMed ID: 30779044
[TBL] [Abstract][Full Text] [Related]
10. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
11. Real-time cytotoxicity assays.
Wlodkowic D; Faley S; Darzynkiewicz Z; Cooper JM
Methods Mol Biol; 2011; 731():285-91. PubMed ID: 21516415
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of complement-dependent cytotoxicity using ATP measurement and C1q/C4b binding.
Broyer L; Goetsch L; Broussas M
Methods Mol Biol; 2013; 988():319-29. PubMed ID: 23475729
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma.
Frankfurt OS; Byrnes JJ; Seckinger D; Sugarbaker EV
Oncol Res; 1993; 5(1):37-42. PubMed ID: 8369574
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
15. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
16. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
18. Developing a novel fiber optic fluorescence device for multiplexed high-throughput cytotoxic screening.
Lee D; Barnes S
J Exp Ther Oncol; 2010; 8(3):235-45. PubMed ID: 20734922
[TBL] [Abstract][Full Text] [Related]
19. High-throughput cytotoxicity and antigen-binding assay for screening small bispecific antibodies without purification.
Sugiyama A; Umetsu M; Nakazawa H; Niide T; Asano R; Hattori T; Kumagai I
J Biosci Bioeng; 2018 Aug; 126(2):153-161. PubMed ID: 29548844
[TBL] [Abstract][Full Text] [Related]
20. Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.
Mandecki W; Ardelt B; Coradetti T; Davidowitz H; AFlint JA; Huang Z; MKopacka WM; Lin X; Wang Z; Darzynkiewicz Z
Cytometry A; 2006 Nov; 69(11):1097-105. PubMed ID: 17051582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
